Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Proteomic response of Enterococcus faecalis with Candesartan Cilexetil treatment

ABSTRACT: Enterococcus faecalis was inoculated and cultured to exponential growth phase (OD600 at 0.5) in TSB and divided into two groups, the control group and the drug treated group. Entrectinib was added to the drug treated group until a final concentration of 1/2× MIC reached, and DMSO added in the control group. Then, cultures in both groups were cultivated for 2 h at 200 rpm. The microbial was centrifuged at 12000 rpm for 10 min, washed twice with Phosphate Buffer Saline (PBS). Lyse the cells by bead-beating at 4 °C in RIPA lysis buffer (1% Triton X-100, 1% deoxycholate, 0.1% SDS), The protein reduction, alkylation and tryptic digestion were followed as filter-aided sample preparation (FASP). The digestion products were analyzed with liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS), followed by label-free quantitative analysis. The MS experiment was performed on a Q Exactive plus mass spectrometer.

ORGANISM(S): Enterococcus Faecalis

SUBMITTER: Zewen Wen

PROVIDER: PXD044400 | iProX | Sat Aug 05 00:00:00 BST 2023

REPOSITORIES: iProX

ACCESS DATA

Json Xml

Similar Datasets

25μM Loratadine and DMSO control group of Enterococcus faecalis biofilm quantitative proteomics comparative study to observe the global expression of protein DMSO treatment group

Project description:S. aureus isolate was inoculated and cultured to radezolid growth phase (OD600 at 0.5) in TSB and divided into two groups, the control group and the drug treated group. Radezolid was added to the drug treated group until a final concentration of 1/2× MIC reached, and DMSO added in the control group. Then, cultures in both groups were cultivated for 2 h at 200 rpm. The microbial was centrifuged at 12000 rpm for 10 min, washed twice with Phosphate Buffer Saline (PBS). Lyse the cells by bead-beating at 4 °C in RIPA lysis buffer (1% Triton X-100, 1% deoxycholate, 0.1% SDS), The protein reduction, alkylation and tryptic digestion were followed as filter-aided sample preparation (FASP). The digestion products were analyzed with liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS), followed by label-free quantitative analysis. The MS experiment was performed on a Q Exactive plus mass spectrometer.

2023-06-20 | PXD043125 | iProX

Staphylococcus aureus biofilm quantitative proteomics comparative study to observe the global expression of protein DMSO treatment group and radezolid treatment group

Project description:S. aureus isolate was inoculated and cultured to exponential growth phase (OD600 at 0.5) in TSB and divided into two groups, the control group and the drug treated group. Radezolid was added to the drug treated group until a final concentration of 1/8× MIC reached, and DMSO added in the control group. Then, cultures in both groups were cultivated for 2 h at 200 rpm. The microbial was centrifuged at 12000 rpm for 10 min, washed twice with Phosphate Buffer Saline (PBS). Lyse the cells by bead-beating at 4 °C in RIPA lysis buffer (1% Triton X-100, 1% deoxycholate, 0.1% SDS), The protein reduction, alkylation and tryptic digestion were followed as filter-aided sample preparation (FASP). The digestion products were analyzed with liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS), followed by label-free quantitative analysis. The MS experiment was performed on a Q Exactive plus mass spectrometer.

2022-11-25 | PXD038354 | iProX

The antibacterial mechanism of Loratadine derivative lo-7 against Streptococcus agalactiae

Project description:Streptococcus agalactiae isolate was inoculated and cultured to exponential growth phase (OD600 at 0.5) in TSB and divided into two groups, the control group and the drug treated group. Loratadine derivative lo-7 was added to the drug treated group until a final concentration of 1/2× MIC reached, and DMSO added in the control group. Then, cultures in both groups were cultivated for 2 h at 200 rpm. The microbial was centrifuged at 12000 rpm for 10 min, washed twice with Phosphate Buffer Saline (PBS). Lyse the cells by bead-beating at 4 °C in RIPA lysis buffer (1% Triton X-100, 1% deoxycholate, 0.1% SDS), The protein reduction, alkylation and tryptic digestion were followed as filter-aided sample preparation (FASP). The digestion products were analyzed with liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS), followed by label-free quantitative analysis. The MS experiment was performed on a Q Exactive plus mass spectrometer.

2023-10-20 | PXD046298 | iProX

proteomic response of S. aureus with BB-Cl-Amidine treatment

Project description:S. aureus isolate was inoculated and cultured to exponential growth phase (OD600 at 0.5) in TSB and divided into three groups, the control group and the drug treated group(1/2× MIC and 1/4× MIC). BB-Cl-Amidine was added to the drug treated group, and DMSO added in the control group. Then, cultures in both groups were cultivated for 2 h at 200 rpm. The microbial was centrifuged at 12000 rpm for 10 min, washed twice with Phosphate Buffer Saline (PBS). Lyse the cells by bead-beating at 4 °C in RIPA lysis buffer (1% Triton X-100, 1% deoxycholate, 0.1% SDS), The protein reduction, alkylation and tryptic digestion were followed as filter-aided sample preparation (FASP). The digestion products were analyzed with liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS), followed by label-free quantitative analysis. The MS experiment was performed on a Q Exactive plus mass spectrometer.

2023-09-05 | PXD045103 | iProX

Proteomic response of S. aureus with baohuoside I

Project description:S. aureus isolate was inoculated and cultured to exponential growth phase (OD600 at 0.5) in TSB and divided into two groups, the control group and the drug treated group. Entrectinib was added to the drug treated group until a final concentration of 1/2× MIC reached, and DMSO added in the control group. Then, cultures in both groups were cultivated for 2 h at 200 rpm. The microbial was centrifuged at 12000 rpm for 10 min, washed twice with Phosphate Buffer Saline (PBS). Lyse the cells by bead-beating at 4 °C in RIPA lysis buffer (1% Triton X-100, 1% deoxycholate, 0.1% SDS), The protein reduction, alkylation and tryptic digestion were followed as filter-aided sample preparation (FASP). The digestion products were analyzed with liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS), followed by label-free quantitative analysis. The MS experiment was performed on a Q Exactive plus mass spectrometer.

2023-07-29 | PXD044207 | iProX

proteomic response of S. aureus with entrectinib treatment

Project description:S. aureus isolate was inoculated and cultured to exponential growth phase (OD600 at 0.5) in TSB and divided into two groups, the control group and the drug treated group. Entrectinib was added to the drug treated group until a final concentration of 1/2× MIC reached, and DMSO added in the control group. Then, cultures in both groups were cultivated for 2 h at 200 rpm. The microbial was centrifuged at 12000 rpm for 10 min, washed twice with Phosphate Buffer Saline (PBS). Lyse the cells by bead-beating at 4 °C in RIPA lysis buffer (1% Triton X-100, 1% deoxycholate, 0.1% SDS), The protein reduction, alkylation and tryptic digestion were followed as filter-aided sample preparation (FASP). The digestion products were analyzed with liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS), followed by label-free quantitative analysis. The MS experiment was performed on a Q Exactive plus mass spectrometer.

2022-11-23 | PXD038342 | iProX

Proteomic response of S. aureus with TAK-285 treated

Project description:S. aureus isolate was inoculated and cultured to exponential growth phase (OD600 at 0.5) in TSB and divided into two groups, the control group and the drug treated group. TAK-285 was added to the drug treated group until a final concentration of 1/2× MIC reached, and DMSO added in the control group. Then, cultures in both groups were cultivated for 2 h at 200 rpm. The microbial was centrifuged at 12000 rpm for 10 min, washed twice with Phosphate Buffer Saline (PBS). Lyse the cells by bead-beating at 4 °C in RIPA lysis buffer (1% Triton X-100, 1% deoxycholate, 0.1% SDS), The protein reduction, alkylation and tryptic digestion were followed as filter-aided sample preparation (FASP). The digestion products were analyzed with liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS), followed by label-free quantitative analysis. The MS experiment was performed on a Q Exactive plus mass spectrometer.

2023-10-24 | PXD046343 | iProX

proteomic response of S. aureus with D-3263 treatment

Project description:S. aureus isolate was inoculated and cultured to exponential growth phase (OD600 at 0.5) in TSB and divided into two groups, the control group and the drug treated group. D-3263 was added to the drug treated group until a final concentration of 1/2× MIC and 1/4× MIC reached, and DMSO added in the control group. Then, cultures in both groups were cultivated for 2 h at 200 rpm. The microbial was centrifuged at 12000 rpm for 10 min, washed twice with Phosphate Buffer Saline (PBS). Lyse the cells by bead-beating at 4 °C in RIPA lysis buffer (1% Triton X-100, 1% deoxycholate, 0.1% SDS), The protein reduction, alkylation and tryptic digestion were followed as filter-aided sample preparation (FASP). The digestion products were analyzed with liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS), followed by label-free quantitative analysis. The MS experiment was performed on a Q Exactive plus mass spectrometer.

2023-10-24 | PXD046347 | iProX

proteomic response of S. aureus with Pinaverium bromide treatment

Project description:S. aureus isolate was inoculated and cultured to exponential growth phase (OD600 at 0.5) in TSB and divided into the control group and two drug treated groups with different concentrations. Pinaverium bromide was added to the drug treated group until a final concentration of 1/2× MIC and 1/4× MIC reached, and DMSO added in the control group. Then, cultures in all groups were cultivated for 2h at 200 rpm. The microbial was centrifuged at 12000 rpm for 10 min, washed twice with Phosphate Buffer Saline (PBS). Lyse the cells by bead-beating at 4 °C in RIPA lysis buffer (1% Triton X-100, 1% deoxycholate, 0.1% SDS), The protein reduction, alkylation and tryptic digestion were followed as filter-aided sample preparation (FASP). The digestion products were analyzed with liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS), followed by label-free quantitative analysis. The MS experiment was performed on a Q Exactive plus mass spectrometer.

2023-01-12 | PXD039378 | iProX

1 / 2 MIC Loratadine and DMSO control group of Streptococcus agalactiae quantitative proteomics to observe the global expression of protein in DMSO treatment group and Loratadine group

Project description:Streptococcus agalaciate isolate was inoculated and cultured to logarithmic growth phase (OD600 at 0.5) in TSB and divided into two groups, the control group and the drug treated group. Loratadine was added to the drug treated group until a final concentration of 1/2MIC reached, and DMSO added in the control group. Then, cultures in both groups were cultivated for 2h. The microbial was centrifuged at 12000 rpm for 10 min, washed twice with Phosphate Buffer Saline (PBS). Lyse the cells by bead-beating at 4 °C in RIPA lysis buffer (1% Triton X-100, 1% deoxycholate, 0.1% SDS), The protein reduction, alkylation and tryptic digestion were followed as filter-aided sample preparation (FASP). The digestion products were analyzed with liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS), followed by label-free quantitative analysis. The MS experiment was performed on a Q Exactive plus mass spectrometer.

2023-07-05 | PXD043548 | iProX

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data